Treatment

Wednesday, 10 September 2008 15:00 - 16:30, Halls B, C and D

Influence of vancomycin MIC on the clinical outcomes in patients with Staphylococcus aureus bacteremia
  • Eun-Young Jang, Asan Medical Center, Korea
Combined efficacy of clarithromycin plus vancomycin in mice with device-related infection by biofilms-forming Staphylococcus aureus
  • Shigeru Fujimura, Research Division for Development of Anti-infected agents, Institute of Development, Aging and Cancer, Tohoku University, Japan
In-vitro activity of dalbavancin against staphylococci
  • Gulseren Aktas, Department of Microbiology and Clinical Microbiology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey., Turkey
In-vitro synergistic activity of daptomycin combined with genetically recombinant antibody against MRSA
  • Ahmed Alharbi, University of Manchester, United Kingdom
Clinical-microbiological substantiaon of “Antoxide”application in the complex therapy of parodont and mouth cavity mucous membrane diseases
  • Perizat Abaskanova, Kyrgyz State Medical Academy, Kyrgyzstan
The impacts of contact time and concentration chlorhexidine to methicillin resistant Staphylococcus aureus (MRSA) growth
  • Enny Suswati Pawukir, Indonesia
The potential of the cationic peptide A415 as a topical therapeutic agent for treating Staphylococcus aureus
  • Mohammed Al-Mahrous, The Univeristy of Manchester, United Kingdom
Furanones can inhibit growth and toxin production by Staphylococcus aureus
  • Mark Willcox, Institute for Eye Research and School of Optometry and Vision Science, Australia
Copper sulfate susceptibility of staphylococci among clinical isolates
  • Michael G Schmidt, Medical University of South Carolina, United States
  • Joseph F John, Charleston Veterans Administration Medical Center, United States
Benzophenanthridine alkaloids effect on planktonic and sessile form of staphylococci
  • Laura Selan, Sapienza University, Rome, ITALY, Italy
A synthetic derivative of natural neolignans from Krameria lappacea (Dombey) Burdet: effect on planktonic and sessile form of staphylococci
  • Marco Artini, Sapienza University, Rome, ITALY, Italy
Inhibition of the staphylococcal pyruvate dehydrogenase multi-enzyme complex by a new class of antibiotics
  • Timo Birkenstock, University of Tuebingen, Germany
  • Andreas Peschel, University of Tuebingen, Germany
Cell division as a novel antibacterial target in Staphylococcus aureus
  • Torsten Theis, Institute for the Biotechnology of Infectious Diseases, University of Technology, Sydney, Australia
Effect of the ozone applied therapy upon staphylococcal microflora and pathogens
  • Eugenia Bezirtzoglou, Democritus University of Thrace, Faculty of Agricultural Development, Laboratory of Microbiology, Biotechnology & Hygiene,, Greece
Spectrum of neutralizing activity against staphylococcal and streptococcal superantigens in IVIG preparations and human plasma
  • Javad Aman, Integrated BioTherapeutics Inc., United States